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INTRODUCTION 
In 2006, the Food and Drug Administration (FDA) approved a vaccine for certain strains 
of the human papillomavirus (HPV), the most common sexually transmitted infection (STI) in the 
United States.
1
  The FDA initially approved this vaccine, Gardasil, only for use in females (age 
twelve through twenty-six) to prevent cervical cancer and genital warts in females caused by 
HPV.
2
  Merck & Co., the vaccine manufacturer, marketed it to adolescent females and parents 
with adolescent daughters as a means of preventing cervical cancer.  In 2009, the FDA approved 
the use of Gardasil in males for the prevention of genital warts.
3
  Although males and females are 
equally susceptible to HPV, and equally likely to transmit the disease to a sexual partner, the 
focus on cervical cancer prevention precludes the inclusion of males in HPV vaccine media 
campaigns and health policies.  The concentration on cervical cancer overshadows discussions of 
other cancers prevented by the vaccine, and stymies the development of comprehensive HPV 
                                                          
* J.D. 2012, University of Pennsylvania.  The author would like to thank Professor Kristen Madison, Sophie Joslin-Roher, 
and Samuel Ostroff for their help with this article. 
1 Gardiner Harris, U.S. Approves Use of Vaccine for Cervical Cancer, N.Y. TIMES, June 9, 2006, at A1. 
2 Id. 
3 FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and 
Guidance From the Advisory Committee on Immunization Practices, 304 JAMA 518, 518 (2010) [hereinafter FDA 
Licensure of HPV Vaccine]. 
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vaccination policies. 
State-mandated vaccinations for school attendance are the most effective means of 
vaccinating a population.  Supreme Court doctrine supports this policy.
4
  However, in the case of 
HPV, there are impediments to a comprehensive vaccination requirement.  Three themes appear 
in arguments against HPV vaccinations: (1) legality; (2) vaccine safety; and (3) adolescent 
sexuality.  First, opponents question the constitutionality of an HPV vaccination mandate because 
HPV is not an airborne disease, as are those targeted by most mandated vaccinations.  The means 
of a disease‟s transmission, however, does not impact its legal analysis, and the Hepatitis B 
vaccine is a prime example of a mandated vaccination for a sexually transmitted disease.  
Additionally, many oppose such legislation because a required vaccination impinges on parental 
autonomy.  Although the Supreme Court supports parental autonomy in the upbringing of 
children,
5
 this privilege is not without limit.
6
  A state‟s right to mandate a vaccination necessarily 
infringes on parental autonomy, and is supported by legal precedent because parents are not 
allowed to subject their children to harm.
7
  Second, opponents question the vaccine‟s long-term 
health effects and its general safety.  Medical research, though, supports the vaccine‟s safety for 
both males and females, and there have been almost no serious adverse events associated with the 
vaccine.
8
  Finally, opponents argue that mandating such a vaccination will increase sexual 
activities by giving adolescents a false sense of security about sex, as well as undercut efforts 
made by abstinence-only education.
9
  These are the two most prominent arguments against the 
vaccine, but nevertheless also fail.  Other cornerstones of safe sex education, like the promotion 
of condoms and emergency contraception, have neither increased sexuality activities, nor 
undercut efforts by abstinence-only education.
10
  As this Article will demonstrate, the arguments 
attacking the vaccine are flawed, and serve only as impediments to its widespread use. 
HPV vaccination conversations need to be shifted away from discussions of adolescent 
sexuality, and policies need to include both males and females.  This Article argues that focusing 
HPV vaccination efforts on females is a mistake with serious health policy consequences.  First, 
vaccines that target only one segment of the population are not effective at reducing the 
prevalence of a communicable disease.  Second, current vaccination policies center on 
heterosexual transmission of the disease, and thus these policies are exclusivist and ignore men 
who have sex with men, a high-risk subgroup for HPV and HPV-related infections, as well as 
                                                          
4 See, e.g., Jacobson v. Massachusetts, 197 U.S. 11 (1905). 
5 See Meyer v. Nebraska, 262 U.S. 390 (1923); Pierce v. Soc‟y of Sisters, 268 U.S. 510, 534–35 (1925) 
(asserting that Meyer v. Nebraska stands for the doctrine that parents have the liberty to “direct the upbringing and 
education of [their] children . . . .”); see also Wisconsin v. Yoder, 406 U.S. 205, 232 (1972) (“This primary role of the 
parents in the upbringing of their children is now established beyond debate as an enduring American tradition.”). 
6 Prince v. Massachusetts, 321 U.S. 158, 166 (1944). 
7 Id. 
8 See infra notes 166–183 for more on the safety and long-term efficacy of the HPV vaccine. 
9 Lane Wood, A Young Vaccine for Young Girls: Should the Human Papillomavirus Vaccination Be 
Mandatory for Public School Attendance?, 20 THE HEALTH LAW. 30, 34 (2007–2008); see also Nancy Gibbs, Defusing 
the War over the ―Promiscuity‖ Vaccine, TIME, June 21, 2006, http://www.time.com/time/nation/article/ 
0,8599,1206813,00.html. 
10 See generally Bradley J. Monk & Dorothy J. Wiley, Will Widespread Human Papillomavirus 
Prophylactic Vaccination Change Sexual Practices of Adolescent and Young Adult Women in America?, 108 OBSTETRICS 
& GYNECOLOGY 420 (2006); see also Amy Bleakley et al., Public Opinion on Sex Education in US Schools, 160 ARCHIVE 
OF PEDIATRIC & ADOLESCENT MED. 1151 (2006). 
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women who have sex with women.
11
  Additionally, current vaccination policies fail to reach low-
income females, who are disparately impacted by HPV and HPV-related cancers.  Instead of 
focusing exclusively on females, vaccination efforts need to be directed at both males and 
females.  State-mandated vaccinations for school attendance reduce disease occurrence and are a 
legal means of creating population-wide immunity.  To ensure maximum coverage, accessibility, 
and immunity, this Article calls for an HPV vaccination requirement for school attendance for 
both adolescent males and females. 
This Article is divided into three parts.  Part I examines HPV, the infections caused by 
the virus, and the incidence of HPV-related diseases in the United States.  This section also 
discusses the efficacy of the HPV vaccine.  Part II provides reasons for comprehensive 
vaccination policies through an examination of the population subgroups ignored by current 
vaccination policies.  This section examines theories of population (herd) immunity, and speaks to 
the issue of whether comprehensive HPV vaccination policies are cost-effective.  Part III argues 
that mandating the HPV vaccination for male and female adolescents for school attendance is 
constitutional and the best way to ensure effective vaccine coverage and adherence.  This Article 
brings together a variety of issues surrounding the current HPV vaccine controversy in order to 
demonstrate that the vaccine is an important health intervention.  A school mandate will ensure a 
sex-neutral and sexuality-neutral approach to eradicating HPV-related cancers and genital 
diseases. 
I. THE HUMAN PAPILLOMAVIRUS 
A. Human Papillomavirus & Cancer 
Human papillomavirus is the most common sexually transmitted infection (STI) in the 
United States,
12
 infecting over 20 million people.
13
  HPV is transmitted through sexual contact, 
typically during vaginal and anal sex, but can also be transmitted through oral sex and genital-to-
genital contact (i.e. skin to skin contact).
14
  According to the National Cancer Society, the only 
way to prevent HPV transmission is by abstaining from all sexual activity; more realistically, 
having sexual contact with fewer partners or with people who do not have a lot of sexual partners 
lowers the risk of HPV infection.
15
  Condoms are helpful in the prevention of HPV,
16
 but because 
                                                          
11 In this article, the terms male and female refer to biological sexes, not genders.  I avoid the use of the term 
“homosexual” in favor of MSM and WSW because the latter terms are commonly used in medical and public health 
discourse. 
12 Human Papillomavirus (HPV), CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/hpv/ 
(last visited Apr. 10, 2012). 
13 Genital HPV Infection – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
std/HPV/STDFact-HPV.htm (last visited Apr. 10, 2012) 
14 Id. 
15 Human Papilloma Virus (HPV), Cancer, and HPV Vaccines: Frequently Asked Questions, AM. CANCER 
SOC‟Y, http://www.cancer.org/Cancer/CancerCauses/OtherCarcinogens/InfectiousAgents/HPV/HumanPapillomaVirusand 
HPVVaccinesFAQ/hpv-faq-how-common-is-hpv#top (last updated Mar. 22, 2012) [hereinafter HPV FAQs, AM. CANCER 
SOC‟Y]. 
16 Marcia L. Shew et al., Association of Condom Use, Sexual Behaviors, and Sexually Transmitted Infection 
with the Duration of Genital Human Papillomavirus Infection Among Adolescent Women, 160 ARCHIVES OF PEDIATRIC & 
ADOLESCENT MED. 151, 155 (2006). 
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it can be passed from genital-to-genital contact the disease can be transmitted prior to condom 
usage.
17
  Cases of HPV are most prevalent in females in their early twenties, and then tend to 
decrease with age.
18
  By contrast, HPV incidence in males is consistent across age ranges; about 
sixty percent of males between the ages of eighteen and seventy have HPV in the United States.
19
 
There are over one hundred strains of HPV,
20
 and about forty of these strains infect the 
genital area.
21
  Ninety percent of cases of HPV infection clear up within two years.
22
  However, 
strains six, eleven, sixteen, and eighteen are considered high-risk because they cause genital 
diseases, including cancers and genital warts.
23
  Strains sixteen and eighteen cause seventy 
percent of all cases of cervical cancer and a significant number of cases of anal, vulva, vaginal, 
penile, and throat, head and neck cancers.
24
  Additionally, strains six and eleven cause about 
ninety percent of all cases of genital warts.
25
  Genital warts and cervical cancer are the two most 
common conditions associated with HPV.
26
 
Approximately five percent of all cancers worldwide are caused by HPV.
27
  There is 
consensus in research and medical communities that HPV not only causes cervical cancer, but is 
responsible for nearly all cases of cervical cancer.
28
  According to the American Cancer Society, 
in 2010 there were 12,200 women who developed new cases of cervical cancer and 4,210 women 
who died from cervical cancer.
29
  The occurrence rate for cervical cancer is 8.1 per 100,000 
females, on average, in the United States.
30
  The death rate for cervical cancer is relatively low: 
2.4 out of 100,000 females with the disease die from it.
31
  Regular pap smears, a routine procedure 
that tests for irregular cells on the cervix, have been effective in catching cancerous cells on the 
                                                          
17 HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 4. 
18 See Micah Globerson, Protecting Women: A Feminist Legal Analysis of the HPV Vaccine, 17 TEX. J. 
WOMEN & L. 67, 69–70 (2007); Sylvia Law, Human Papillomavirus Vaccination, Private Choice, and Public Health, 41 
U.C. DAVIS L. REV. 1731, 1733 (2008). 
19 Shari Roan, HPV: Men Can Get it Too, L.A. TIMES, Mar. 19, 2007, at F1; see also ANNA R. GIULIANO ET 
AL., INCIDENCE AND CLEARANCE OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN MEN (HIM): A COHORT STUDY 6 
(2011) [hereinafter GIULIANO ET AL., INCIDENCE AND CLEARANCE] (asserting that: “Whereas risk of HPV decreases with 
increasing age in women, men seem to have a stable risk for acquiring new HPV infections throughout their life.”). 
20 Gail Javitt et al., Assessing Mandatory HPV Vaccination: Who Should Call the Shots?, 36 J. L. MED. & 
ETHICS 384, 385 (2008). 
21 Genital HPV Infection – Fact Sheet, supra note 13. 
22 Id. 
23 Javitt et al., supra note 20, at 385. 
24 Id.; see also Hisham Mehanna et al., Head and Neck Cancer – Part I: Epidemiology, Presentation, and 
Prevention, 341 BRIT. J. MED. 663, 664 (2010) [hereinafter Mehanna et al., Head and Neck Cancer]. 
25 Javitt et al., supra note 20, at 385. 
26 Genital HPV Infection – Fact Sheet, supra note 13. 
27 Anil K. Chaturvedi, Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and 
Women, 46 J. ADOLESCENT HEALTH S20, S20 (2010). 
28 Id. at S21; see also HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 4. 
29 AM. CANCER SOC‟Y, CANCER FACTS AND FIGURES 2010 4 (2010), available at http://www.cancer.org 
/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf [hereinafter CANCER FACTS AND 
FIGURES]. 
30 SEER Stat Fact Sheet: Cervical Uteri, NAT‟L CANCER INST., http://www.seer.cancer.gov/statfacts/html 
/cervix.html (last visited Apr. 10, 2012). 
31 Id. 
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cervix at an early stage and preventing the development of cervical cancer.
32
  Some argue that 
there is no need for a vaccine, because regular exams and screenings, when available, are 
effective, less costly, and do not involve shots.
33
 
Although pap smears are effective at preventing cervical cancer, they do not screen for 
all cancers caused by HPV infection, and the rates and prevalence of these other cancers are not 
insignificant.  HPV causes eighty to ninety percent of anal cancers, which is a growing problem in 
the United States, affecting males and females alike.  Between 1994 and 2000, anal cancer 
occurrence increased for both males and females.
34
  In 2010, there were an estimated 5,000 new 
cases of anal cancer in the United States: 2,000 new cases among males, and 3,000 among 
females.
35
  The incidence rate is 1.6 per 100,000 males and females per year.
36
  The death rate 
from anal cancer is 0.2 per 100,000 individuals, both males and females.
37
  Females who have 
HPV-related cervical or vulva cancer are at a higher risk for anal cancer because of previous 
exposure to cancerous HPV infection.
38
  Most cases of anal cancer are found in men who have sex 
with men (MSM) and in females who have sex with males.  However, studies show that there is a 
growing presence of anal cancer among males who have sex with females, which raises questions 
about how this particular disease develops once HPV is transmitted.
39
 
In addition to cervical and anal cancer, HPV also causes an estimated forty to sixty-four 
percent of vaginal cancer cases, and forty to fifty-one percent of vulva cancer cases in females.
40
  
In 2010, there were an estimated 2,300 new cases of vaginal cancer and 3,900 new cases of vulva 
cancer.
41
  For vulva cancer, there is an occurrence rate of 2.4 per 100,000 females in the United 
States, and a death rate of approximately 0.5 per 100,000 females.
42
  The National Cancer 
Institute does not compile occurrence data on vaginal cancer because it is considered a rare 
cancer.  HPV also causes thirty-six to forty percent of penile cancer cases.
43
  In 2010, there were 
an estimated 1,250 new cases of penile cancer in the United States.  Finally, HPV has also been 
found to cause throat, head and neck cancers.
44
  Of the 49,200 new cases of throat cancer in the 
                                                          
32 Chaturvedi, supra note 27, at S23; see also Eliav Barr et al., Impact of a Prophylactic Quadrivalent 
Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle Vaccine in a Sexually Active Population of North 
American Women, 198 AM. J. OBSTETRICS & GYNECOLOGY 261.e1, 261.e1 (2008). 
33 Judy Peres, Who Should Get the HPV Vaccine? Usage Expands Amid Debate, 102 J. NAT‟L CANCER 
INST. 838, 840 (2010). 
34 Djenaba A. Joseph et al., Understanding the Burden of Human Papillomavirus Associated Anal Cancers 
in the United States, 113 CANCER 2892, 2892–93 (2008); see generally, Lisa G. Johnson et al., Anal Cancer Incidence and 
Survival: The Surveillance, Epidemiology, and End Results Experience, 1973 – 2000, 101 CANCER 281 (2004) (explaining 
trends in the incidence of anal cancer for various groups over time). 
35 CANCER FACTS AND FIGURES, supra note 29, at 4. 
36 SEER Stat Fact Sheet: Cervical Uteri, supra note 30. 
37 Id. 
38 Joseph et al., supra note 34, at 2893. 
39 Alan G. Nyitray et al., Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Men 
who have Sex with Women: A Cross National Study, 201 J. INFECTIOUS DISEASES 1498, 1504 (2010). 
40 Chaturvedi, supra note 27, at S21 (citing studies conducted in 2006 and 2008). 
41 CANCER FACTS AND FIGURES, supra note 29, at 4. 
42 SEER Stat Fact Sheet: Cervical Uteri, supra note 30. 
43 Nyitray et al., supra note 39, at 1504. 
44 See generally Gypsyamber D‟Souza et al., Case–Control Study of Human Papillomavirus and 
Oropharyngeal Cancer, 356 NEW ENG. J. MED. 1944 (2007) (finding a strong association between oral HPV infection and 
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United States in 2010,
45
 HPV caused about twelve to sixty percent.
46
  According to the British 
Journal of Medicine, head and neck cancer is the sixth most prevalent cancer in the world.
47
  




In addition to cancer, high-risk strains of HPV also cause genital warts.
49
  Every year in 
the United States, about 500,000 people acquire genital warts
50
 and ninety percent of all cases of 
genital warts are attributed to HPV infection.
51
  Genital warts afflict both males and females, but 
typically have a longer duration of infection in males.
52
  Although the medical effects of genital 
warts are relatively limited, many doctors cite the psychological affects, such as stress and 
embarrassment, as more serious consequences of the disease.
53
  Recurrence of genital warts is 
also quite common.
54
  Additionally, the HPV strains that cause genital warts can also lead to 




Not surprisingly, because cervical cancer is the most significant consequence of HPV, 
HPV is viewed as a female problem, and specifically a heterosexual female problem.
56
  Males are 
typically perceived as transmitters of the infection who increase the cervical cancer risk in 
females, but they are not perceived as personally at risk.
57
  This perception is incorrect.  While the 
majority of males who contract HPV are asymptomatic, HPV does lead to negative health 
                                                          
cancer of the throat). 
45 CANCER FACTS AND FIGURES, supra note 29, at 4. 
46 Chaturvedi, supra note 27, at S21.  The statistics for throat cancer are harder to determine because of the 
other risk factors associated with the disease, including tobacco inhalation and alcohol consumption, can also be present.  
CANCER FACTS AND FIGURES, supra note 29, at 17.  Additionally, researchers found that HPV-related neck and head 
cancer are significantly different than other types of these cancers.  See Mehanna et al., Head and Neck Cancer, supra note 
24, at S21 (“HPV related oropharyngeal carcinoma is a distinct disease entity.  Patients are younger (usually 40-50 years 
old), often do not report the usual risk factors of smoking or high alcohol intake, and often present with a small primary 
tumour and large neck nodes.”). 
47 Hishman M. Mehanna, Oropharyngeal Carcinoma Related to Human Papillomavirus, 340 BRIT. J. MED. 
879, 879 (2010) [hereinafter Mehanna, Oropharyngeal Carcinoma]. 
48 Id. 
49 Anna R. Giuliano et al., Epidemiology and Pathology of HPV Disease in Males, 117 GYNECOLOGIC 
ONCOLOGY S15, S15 (2010) [(hereinafter Giuliano et al., Epidemiology of HPV]. 
50 Jan Hoffman, Vaccinating Boys for Girls’ Sake?, N.Y. TIMES, Feb. 24, 2008, at ST1, ST10. 
51 Sexually Transmitted Disease Treatment Guidelines 2010 – Genital Warts, CTRS. FOR DISEASE CONTROL 
& PREVENTION, http://www.cdc.gov/std/treatment/2010/genital-warts.htm (last visited Apr. 10, 2012). 
52 Anna R. Giuliano, Human Papillomavirus Vaccination in Males, 170 GYNECOLOGIC ONCOLOGY S24, 
S25 (2007) [hereinafter Giuliano, HPV Vaccination]. 
53 Hoffman, supra note 50, at ST10; see also Giuliano et al., Epidemiology of HPV, supra note 49, at S15. 
54 Giuliano et al., Epidemiology of HPV, supra note 49, at S15. 
55 Gregory D. Zimet, Potential Barriers to HPV Immunization: From Public Health to Personal Choice, 35 
AM. J. L. & MED. 389, 389 (2009) [hereinafter Zimet, Potential Barriers]. 
56 See infra notes 91–102 for data on HPV and HPV-related diseases among women who have sex with 
women. 
57 Joel M. Palefsky, Human Papillomavirus-Related Disease in Men: Not Just a Women’s Issue, 46 J. 
ADOLESCENT HEALTH S12, S12 (2010). 
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consequences in males, including anal, penile, and throat cancers, and genital warts.
58
  HPV in 
males, because it is mostly undetected and thus untreated, can weaken immune systems, and some 
data suggests that it makes affected males more susceptible to HIV.
59
  HPV is particularly 
problematic in the MSM population, whose members are seventeen times more likely to contract 
HPV than males who only have sex with females.
60
  The risk of developing HPV-related diseases 
is also significantly higher in this segment of the male population.
61
 
HPV is widely assumed to be a relatively harmless STI.  However, the high-risk strains 
of the disease are not.  HPV is a serious public health issue.  The HPV vaccine offers an avenue 
for cancer and disease reduction, and thus should be used with more frequency to prevent the 
spread of the high-risk strains of HPV. 
B. The HPV Vaccine: Quadrivalent Gardasil 
In June 2006, the Food and Drug Administration (FDA) approved Merck‟s Gardasil, a 
quadrivalent HPV vaccine that protects against strains six, eleven, sixteen, and eighteen of HPV 
for the prevention of cervical cancer and genital warts in females only.
62
  For females, studies 
from drug trials showed that the quadrivalent vaccine significantly reduced the occurrence of 
genital cancerous lesions and genital warts.
63
  In some studies, the vaccine was proven nearly 
100% effective in preventing the genital diseases associated with HPV in females.
64
  In October 
2009, the FDA approved Cervarix, a bivalent HPV vaccine manufactured by GlaxoSmithKline 
Biologicals, for use in females for the prevention of cervical cancer caused by HPV strains sixteen 
and eighteen.
65
  Although this Article‟s arguments and conclusions are relevant for Cervarix, this 
Article will focus on Gardasil, the quadrivalent vaccine, for two main reasons: (1) most of the 
clinical research has been conducted on the quadrivalent vaccine; and (2) as of February 2012, 
Cervarix has not yet been approved for use in males. 
In October 2009, the FDA approved Gardasil for males, aged nine through twenty-six, 
for the prevention of genital warts caused by HPV strains six and eleven.
66
  In drug trials on 
males, the quadrivalent vaccine demonstrated high levels of efficacy in reducing the occurrence of 
                                                          
58 HPV & Men – Fact Sheet, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/std/hpv/ 
stdfact-hpv-and-men.htm (last visited Apr. 10, 2012) [hereinafter CDC, HPV & Men]. 
59 Palefsky, supra note 57, at S12 (“[R]ecent data suggests that HPV infection in men may increase the risk 
of acquiring human immunodeficiency virus (HIV) infection.”).  HPV is also a serious health problem for HIV-positive 
individuals.  However, this article focuses only on HIV-negative segments of the population. 
60 See CDC, HPV & Men, supra note 58. 
61 See Jane J. Kim, Targeted Human Papillomavirus Vaccine of Men Who Have Sex with Men in the USA: a 
Cost-Effectiveness Modelling Analysis, 10 LANCET INFECTIOUS DISEASES 845 (2010) (discussing the risks of anal cancer, 
developed from HPV, in MSM) [hereinafter Kim, Targeted HPV Vaccine]. 
62 See Harris, supra note 1; see also GARDASIL, http://www.gardasil.com/ (last visited Apr. 10, 2012). 
63 Barr et al., supra note 32, at 261.e1 (2008) (describing studies conducted on North American women); see 
also Suzanne M. Garland et al., Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases, 
356 NEW ENG. J. MED. 1928, 1935 (2007) (describing studies conducted on women across the world). 
64 Garland et al., supra note 63, at 1935. 
65 Press Release, Food & Drug Admin., FDA Approves New Vaccine for Prevention of Cervical Cancer 
(Oct. 16, 2009), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm (last 
visited Apr. 10, 2012). 
66 FDA Licensure of HPV Vaccine, supra note 3, at 518. 
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genital cancerous lesions and genital warts.
67
  Although the vaccine did have lower rates of 
efficacy in males than in females, it was shown to reduce the rate of HPV infection in males by 
sixty-five percent.
68
  While early approvals of the use of Gardasil were based on its use to help 
prevent cervical cancer in females and genital warts in males, it is now recognized as efficacious 
in preventing anal cancer as well.  In December 2010, the FDA approved Gardasil for the 
prevention of anal cancer in both sexes.
69
 
The use of Gardasil is strongly supported by federal agencies.  The Advisory Committee 
in Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention 
(CDC) and the Department of Health and Human Services (HHS), recommended the 
administration of the vaccine for both males and females.  The ACIP is a crucial part of state and 
federal vaccination policies.  The ACIP is an external, non-partisan group, made up of fifteen 
medical experts not employed by the United States government, that issues policy 
recommendations to the CDC and HHS.
70
  The ACIP was formed in 1964 to provide outside 
expert advice and guidance to the CDC and HHS on the use of vaccines in civilian populations.
71
  
ACIP recommendations dictate national vaccination policy and play an essential role in the 
control of contagious diseases in the United States.  ACIP recommendations reach beyond the 
federal government, and are largely followed by states in determining vaccination policies.
72
  In 
2009, the ACIP recommended routine administration of the HPV vaccine for females.  When the 
ACIP first approved the HPV vaccine for males, the group gave a somewhat “lesser” 
recommendation for males, while still asserting that the vaccine may be given to males.
73
  
However, in October 2011, the ACIP changed their recommendation, and now recommends 
routine administration of the HPV vaccine for boys.
74
  The ACIP advocated for the availability of 
Gardasil to males and females through Vaccines for Children,
75
 a federal program that funds 
routine vaccinations for children who are unable to afford the vaccine.
76
 
As discussed previously, the HPV vaccine is effective in preventing HPV and helping to 
avoid HPV-related health conditions.  For the vaccine to be the most effective, however, it must 
                                                          
67 Anna R. Giuliano et al., Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in 
Males, 364 NEW ENG. J.  MED. 401, 409 (2011) [hereinafter Giuliano, HPV Vaccine in Males]. 
68 Id. 
69 Press Release, Food and & Drug Admin., FDA: Gardasil Approved to Prevent Anal Cancer (Dec. 22, 
2010) available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm237941.htm; see also Jane J. 
Kim, Weighing the Benefits and Costs of HPV Vaccination of Young Men, 364 NEW ENG. J. MED. 393, 394 (2011) 
(exploring the societal and health cost and benefits of providing the HPV vaccine to young men). 
70 Jean C. Smith et al., Immunization Policy Development in the United States: The Role of the Advisory 
Committee on Immunization Practices, 150 ANNALS INTERNAL MED. 45, 45 (2009). 
71 Id. 
72 Amber Oleson, Legislative Update: Should the Human Papillomavirus Vaccine be Mandated for Pre-
Adolescent Girls? The HPV Vaccine Becomes a Political Issue, 28 CHILD. LEGAL RTS. J. 64, 66 (2008). 
73 FDA Licensure of HPV Vaccine, supra note 3, at 518. 
74 Gardiner Harris, Panel Endorses HPV Vaccine for Boys of 11, N.Y. TIMES, Oct. 26, 2011, at A1. 
75 N. Liddon et al., Provider Attitudes Towards HPV Vaccines for Males, 47 J. ADOLESCENT HEALTH 1, 1 
(2010); see also Lauri E. Markowitz et al., Quadrivalent Human Papillomavirus Vaccine: Recommendations of the 
Advisory Committee on Immunization Practices (ACIP), 56 MORBIDITY & MORTALITY WEEKLY REPORT 1, 16 (2007), 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm?s_cid=rr5602a1_e. 
76 Vaccines for Children Program, CTRS. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/ 
vaccines/programs/vfc/default.htm (last visited Apr. 10, 2011). 
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be administered before any HPV exposure.
77
  As a prophylactic drug, and not a therapeutic one, 
Gardasil is only effective in preventing certain strains of HPV, and not treating them once 
acquired.
78
  Due to the time sensitive nature of Gardasil,
 
many argue it should be mandated to 
ensure timely adherence.
79
  Additionally, it is argued that the focus of any HPV vaccination 
policies should be on adolescents to ensure that they are immunized prior to HPV exposure.  The 
next section of this Article demonstrates why both males and females need to be included in any 
routine, comprehensive vaccination policy in order to better immunize the population against the 
high-risk strains of HPV. 
II. WHY AN INCLUSIVE HPV VACCINATION POLICY IS NECESSARY 
Current HPV vaccination policies are exclusive and woefully ineffective.  At the 
moment, the HPV vaccine administration targets only females and has not reduced occurrences of 
HPV across the population.  The narrow focus of HPV vaccination policies on females is 
problematic because the vaccine is not achieving desired population-level immunity.  This 
ineffectiveness stems from the fact that these policies explicitly fail to include all males, 
specifically men who have sex with men, and implicitly exclude certain subgroups of females, 
including low-income females and women who have sex with women.  This section examines the 
problems with current vaccination policies by highlighting the exclusion of certain subgroups of 
the population, and by discussing concepts of population-wide immunity and the failures of other 
vaccines that targeted only certain segments of the population.  This section will demonstrate why 
comprehensive and inclusive vaccination programs that target all members of the population will 
be the most effective means of reducing the occurrence of HPV and HPV-related cancers in the 
United States. 
A.  Ignored Subgroups 
Current vaccination policies fail to include three particular subgroups of the population: 
men who have sex with men (MSM); women who have sex with women (WSW); and low-
income women, particularly those of color.  MSM and WSW are both excluded from current 
vaccination policies because of the focus of such policies on the heterosexual transmission of the 
disease.  Although MSM are a high-risk population for HPV, there are many barriers to successful 
administration of the vaccine without a formal vaccination mandate.  Dr. Jane Kim of the Harvard 
School for Public Health argues that “[s]everal obstacles challenge early uptake in this high-risk 
subgroup, including age at which people self-identify as MSM [and] willingness to disclose 
sexual identity to others,”
80
 all of which prevent the administration of the vaccine prior to HPV 
exposure.  The fact that this vaccine is one that must be requested further places the HPV vaccine 
out of reach for many low-income women because of the lack of comprehensive reproductive 
health services available to this population.  Thus, as is evidenced by this section, a sexuality-
neutral vaccination policy, accompanied with easy accessibility, is essential for the success of the 
HPV vaccine. 
                                                          
77 HPV FAQs, AM. CANCER SOC‟Y, supra note 15, at 8–9. 
78 Wood, supra note 9, at 31. 
79 Law, supra note 18, at 1764 (“[Y]oung people are far more likely to receive a timely vaccination prior to 
contracting the virus if vaccination is mandatory.”). 
80 Kim, Targeted HPV Vaccine, supra note 61, at 850. 
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1. Men Who Have Sex with Men 
The current focus on females for the administration of the HPV vaccine completely 
ignores an entire population of men who have sex with men.  MSM have a higher risk for HPV-
related genital warts and anal cancer compared to males who only have sex with females.
81
  MSM 
also have a greater risk for anal cancer than the population in general.
82
  The risk and prevalence 
of anal cancer in the MSM population is arguably higher than cervical cancer for females in the 
United States.
83
  Although this can be attributed to the high prevalence of vaginal pap smears and 
cervical cancer screenings for females,
84
 and the relative lack of anal pap smears for males,
85
 it 
highlights the dangers of HPV-related cancers for males in this subgroup.  Additionally, unlike 
incidences of cervical cancer, which tend to decrease as females age, incidences of anal cancer 
remain constant throughout the sexual lifespan of MSM.
86
 
Mandating the vaccination is the most effective and efficient means of protecting the 
MSM subgroup because the mere availability of the vaccine will not ensure appropriate use for 
this segment of the population.  Many studies show that MSM do not openly admit their sexual 
preferences until almost two years after their first sexual contact and after having a number of 
sexual partners.
87
  This affects the efficacy of administering the vaccine to MSM because the drug 
must be administered prior to exposure to HPV for maximum effectiveness.
88
  Targeting this 
subgroup for voluntary vaccination would be futile because the drug needs to be administered 
prior to exposure, and would be ineffective, and a waste of resources, to administer the vaccine to 
a population that has already been exposed to HPV.
89
  One researcher for the National Cancer 
Institute argued that the vaccine should be offered to all males because “it‟s impossible to know 
which preadolescent boys will grow up to become men who have sex with men, [and thus] it 
would not be feasible to target the vaccine to that subgroup of males.”
90
 
2. Women Who Have Sex with Women 
Discourse around female sexual health focuses on heterosexual females, and there is 
documented evidence that WSW do not receive the same level of sexual health care as 
                                                          
81 CDC, HPV & Men, supra note 58; see also Paul L. Reiter et al., Acceptability of HPV Vaccine Among a 
National Sample of Gay and Bisexual Men, 37 SEXUALLY TRANSMITTED DISEASES 197, 197 (2010). 
82 Reiter et al., supra note 81, at 197. 
83 Marian Pitts et al., What do Gay Men Know About Human Papillomavirus? Australian Gay Men’s 
Knowledge and Experience of Anal Cancer Screening and Human Papillomavirus, 34 SEXUALLY TRANSMITTED 
DISEASES 170, 170 (2007).  Although Pitts‟ data focuses on Australia, the main ideas of her article are applicable to the 
United States as well because of Australia‟s status as a Western country that regularly employed vaginal pap smears and 
cervical cancer screenings for females. 
84 Chaturvedi, supra note 27, at S23; see also Barr et al., supra note 32, at 261. 
85 Pitts et al., supra note 83, at 171–72. 
86 Peter V. Chin-Hong et al., Age-Related Prevalence of Anal Cancer Precursors in Homosexual Men: The 
EXPLORE Study, 97 J. NAT‟L CANCER INST. 896, 904 (2005). 
87 D. Simatherai et al., What Men Who Have Sex With Men Think About the Human Papillomavirus Vaccine, 
85 SEXUALLY TRANSMITTED INFECTION 148, 149 (2009). 
88 Id. 
89 Id. 
90 Peres, supra note 33, at 840. 
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heterosexual females.  Feminist scholars posit “medicine constitutes a particularly powerful 
instrument of support for the coercive institution of heterosexuality.”
91
  Sexual health policies 
typically focus on heterosexual females, and the heterosexual transmission of STIs.  There are an 
estimated 2.3 million females in the United States who self-identify as WSW.
92
  Sex between 
females is typically viewed as safer, and thus, WSW do not typically view themselves as at risk 
for HPV.
93
  However, studies demonstrate that WSW do have similar risk levels for, and 
incidences of, HPV and cervical cancer as heterosexual females.
94
  About thirteen percent of 
WSW are infected with some strain of HPV.
95
  HPV can be transmitted through oral and vaginal 
sex between females, particularly when sex toys are shared.
96
  Additionally, studies have shown 
that HPV is transmitted from skin-to-skin contact so that penetration is not a necessary act for 
acquiring the disease.
97
  One study asserted that it is a “popular misconception that lesbians are at 
a decreased risk for cervical cancer compared to heterosexual women.”
98
  Because of this 
misconception, there are fewer WSW who get yearly pap smears,
99
 and thus such females are 
more at risk for cervical cancer because pap smears are proven to be effective at catching the 
disease early.  Scholars argue that WSW “often avoid accessing health care because of real or 
perceived homophobia and heterosexism . . . [t]herefore, routine screenings are not performed and 
cancers may be detected at later, less treatable stages.”
100
  Medical professionals assert that WSW 
need to be encouraged to have regular pap smears, just as heterosexual females are encouraged to 
do so yearly.
101
  Genital warts can also affect the WSW subgroup; however, the prevalence of this 
infection is significantly lower than among heterosexual females and males, and the MSM 
subgroup.
102
  By creating vaccination policies that are universal and sex- and sexuality-neutral, 
                                                          
91 Virginia Braun & Nicola Gavey, ―Bad Girls‖ and ―Good Girls‖?: Sexuality and Cervical Cancer, 22 
WOMEN‟S STUD. INT‟L FORUM 203, 209 (1999) (citing SUSAN SHERWIN, NO LONGER PATIENT: FEMINIST ETHICS AND 
HEALTH CARE 213 (1992)). 
92 Jeanne M. Marrazzo & Kathleen Stine, Reproductive Health History of Lesbians: Implications for Care, 
190 AM. J. OBSTETRICS & GYNECOLOGY 1298, 1298 (2004). 
93 Lisa Eaton et al., Perceived Prevalence and Risks for Human Papillomavirus (HPV) Infection among 
Women Who Have Sex with Women, 17 J. WOMEN‟S HEALTH 75, 80 (2008). 
94 See generally Jeanne M. Marrazzo et al., Genital Human Papillomavirus Infection in Women Who Have 
Sex With Women, 178 J.  INFECTIOUS DISEASES 1604 (1998) (finding that HPV is common among women who have sex 
with women even if they have not had sex with men). 
95 Eaton et al., supra note 93, at 76. 
96 Jennifer Power et al., Absent Sexual Scripts: Lesbian and Bisexual Women’s Knowledge, Attitudes and 
Actions Regarding Safer Sex and Sexual Health Information, 11 CULTURE, HEALTH & SEXUALITY 67, 69 (2009) (citing a 
study conducted in 2000). 
97 Luisa Lina Villa, Prophylactic HPV Vaccines: Reducing the Burden of HPV-Related Diseases, 24 
Supplement 1 VACCINE S1/23, S1/23 (2006) (“HPV DNA has been reported in approximately 20% of women who have 
never had vaginal intercourse, suggesting that abstaining from penetrative intercourse is not completely protective against 
infection.”). 
98 Jessica P. Brown & J. Kathleen Tracey, Lesbians and Cancer: An Overlooked Health Disparity, 19 
CANCER CAUSES & CONTROL 1009, 1016 (2008). 
99 Jeanne M. Marrazzo, Genital Human Papillomavirus Infection in Women Who Have Sex with Women: A 
Concern for Patients and Providers, 14 AIDS PATIENT CARE & STDS 447, 449 (2000). 
100 Carolee Polek & Thomas Hardie, Lesbian Women and Knowledge about Human Papillomavirus, 37 
ONCOLOGY NURSING FORUM E191, E196 (2010). 
101 Marrazzo et al., supra note 94, at 1608. 
102 See generally JV Bailey et al., Sexually Transmitted Infections in Women Who Have Sex With Women, 80 
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the vaccine will reach all females.  Vaccination campaigns and policies that focus on heterosexual 
sex and transmission adversely affect WSW and are simply bad health policies. 
3.  Low Income Females 
Mandating the vaccination will not only create a sexuality-neutral policy, but also a race-
neutral and income-neutral policy.  Studies show that low-income populations have higher rates 
of sexually transmitted infections.
103
  Women of color in the United States are more likely to be in 
this subgroup, many of whom are uninsured and have less access to cervical cancer screenings 
and regular pap smears.
104
  African American females and Hispanic females have a greater 
likelihood of having cervical cancer
105
 and also have a significantly higher risk of death from the 
disease than Caucasian females.
106
  Mandating the vaccination will protect low-income 
populations and prevent racial minorities from experiencing a negative disparate impact from the 
burdens of HPV because the vaccine will be more readily accessible.
107
  Although it is argued that 
low-income adolescents can get the vaccine through the Vaccines for Children program, the only 
way to ensure universal coverage is to mandate the vaccination because this will ensure that all 
members of the population receive the vaccine.
108
 
B.  Herd Immunity 
Vaccines are more effective when given to both sexes, because as more people get 
vaccinated, the general immunity of the entire population (i.e. the herd) increases.
109
  Herd 
immunity is “the population-level consequence of acquired immunity among some individuals 
that can reduce the risk of acquiring infection among susceptible individuals.”
110
  Herd immunity 
is the goal of all mass immunization programs and is based on the belief that immunizing a 
certain portion of the population will create general immunity throughout the population at 
large.
111
  Herd immunity protects persons who have and have not been immunized.  Those who 
                                                          
SEXUALLY TRANSMITTED INFECTIONS 244 (2004) (finding that it is possible for sexually transmitted diseases to occur 
between women); Katherine Fethers et al., Sexually Transmitted Infections and Risk Behaviours in Women Who Have Sex 
With Women, 76 SEXUALLY TRANSMITTED INFECTIONS 345 (2000) (finding higher STD transmission among women who 
have sex with women than the control population of the study). 
103 Sara E. Forhan et al., Prevalence of Sexually Transmitted Infections Among Female Adolescents Aged 
14-19 in the United States, 124 PEDIATRICS 1505, 1510 (2009). 
104 Law, supra note 18, at 1764–65. 
105 Id. at 1765 (finding Hispanic women have the highest rates of cervical cancer and that African American 
women are fifty percent more likely to experience cervical cancer than white women). 
106 Globerson, supra note 18, at 73. 
107 See Law, supra note 18, at 1764 (stating that a disproportionate number of women of color will die 
unnecessarily if they are not vaccinated at a young age). 
108 Wood, supra note 9, at 34. 
109 Palefsky, supra note 57, at S16; see also Gregory D. Zimet & Susan L. Rosenthal, HPV Vaccine and 
Males: Issues and Challenges, 117 GYNECOLOGIC ONCOLOGY S26, S29 (2010) (stating that gender-based vaccinations 
policies are less effective and more confusing to the public). 
110 Geoffrey P. Garnett, Role of Herd Immunity in Determining the Effect of Vaccines against Sexually 
Transmitted Disease, 191 J.  INFECTIOUS DISEASES S97, S98 (2005). 
111 Id. at S98; see also Javitt et al., supra note 20, at 388. 
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are susceptible are protected because high levels of population immunity reduce the likelihood 




Herd immunity is central to arguments for mandating vaccines in general,
113
 and for the 
HPV vaccine, in particular.  The ultimate goal of any vaccination program is the complete 
eradication of the intended disease.  However, policymakers and medical professionals 
acknowledge that this is an impossible goal,
114
 and thus, strategic control of the disease is the 
focus of vaccination policies.  High vaccine coverage is necessary for herd immunity.
115
  
Although there are varying thresholds for population-level immunity for any given infectious 
disease, the basic premise behind herd immunity is to vaccinate as many members of the 
population as possible to create the highest attainable level of general immunity.
116
 
Some argue that if all females are vaccinated, then males will be covered by herd 
immunity as well.  However, this argument fails.  For cervical cancer prevention, specifically, 
many researchers and physicians agree that it is important to vaccinate males to prevent the 
transmission of HPV to females
117
 because studies have shown that the transmission of HPV from 
males to their female partners leads to a significant number of cervical cancer cases.
118
 
Studies of other infectious diseases demonstrate that vaccinating only one segment of the 
population does not decrease disease incidence, and in some cases actually increases transmission 
overall.
119
  Two prime examples are the Rubella and Hepatitis B vaccines.  These two vaccination 
policies failed because both were initially introduced to only a segment of the population and 
were unsuccessful at reducing the occurrence of the disease.  The Rubella vaccine was initially 
offered to only females, to protect them from the dangers of the disease during pregnancy.
120
  
However, these female-only policies neither lowered the incidence rates of Rubella nor created 
generally immunity.  It was not until the Rubella vaccine was given to the general population, 
through state vaccination mandates, that the disease was basically eradicated.
121
 
When the FDA approved the Hepatitis B vaccine, it was only offered to certain segments 
of the population, and consequently, the prevalence of the disease remained high.
122
  A reduction 
                                                          
112 Garnett, supra note 110, at S98. 
113 Id. at S98. 
114 Paul Fine et al., ―Herd Immunity‖: A Rough Guide, 52 CLINICAL INFECTIOUS DISEASES 911, 914 (2011). 
115 Giuliano, HPV Vaccination in Males, supra note 67, at S26. 
116 Fine et al., supra note 114, at 914–15. 
117 Thomas W. Weiss et al., Human Papillomavirus Vaccination of Males: Attitudes and Perceptions of 
Physicians Who Vaccinate Females, 47 J. ADOLESCENT HEALTH 3, 9 (2010). 
118 Giuliano, HPV Vaccination in Males, supra note 67, at S25 (citing studies that show that cervical cancer 
in females with one lifetime sexual partner is typically caused by HPV transmission by the male‟s partner, and that 
promiscuity in males greatly increases risks of cervical cancer in females). 
119 Id. at S25–26. 
120 Id. 
121 Id.; see also Jennifer Caseldine-Bracht, The HPV Vaccine Controversy: Where are the Women? Where 
are the Men? Where is the Money?, 3 INT‟L J.  FEMINIST APPROACHES TO BIOETHICS 99, 104 (2010) (“When the rubella 
vaccine was introduced in the 1960s, it was originally recommended that only women of child-bearing age get inoculated.  
However, only when both boys and girls got the vaccine was rubella finally eradicated.”). 
122 Sheila M. Rothman & David J. Rothman, Marketing HPV Vaccine: Implications for Adolescent Health 
and Medical Professionalism, 302 JAMA 781, 782 (2009). 
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in Hepatitis B only occurred after states adopted universal vaccination policies.
123
  The 
experiences of the Rubella and Hepatitis B vaccines demonstrate that vaccination polices are 
neither an effective means of reducing the prevalence of disease nor are they successful at 
establishing herd immunity when one segment of the population is targeted.  Males need to be 
included in vaccination policies to establish an effective level of herd immunity, which will stop 
the spread of HPV, and thus reduce the incidences of HPV-related cancer and genital disease. 
Some experts have questioned whether it is cost-effective to vaccinate males in addition 
to females.  Gardasil is the most expensive vaccine recommended by the ACIP,
124
 and all three 
doses of the shot cost about $360 per person.
125
  Although many studies suggest that vaccinating 
males is not cost-effective, these studies only look at cervical cancer prevention and fail to include 
cancers and infections that affect males.
126
  A 2010 study demonstrated that it is cost-effective to 
include males in vaccination programs when focusing on the benefits to males and females and 
including all cancers and infections caused by HPV in the analysis.
127
  This inclusive study 
concluded that when the focus is expanded beyond cervical cancer, it is cost-effective to vaccinate 
both males and females.  Moreover, current studies on the cost-effectiveness of the vaccine for 
both males and females focus solely on heterosexual transmission of the disease between males 
and females and fail to include the benefits of the vaccine for men who have sex with men (MSM) 
and women who have sex with women (WSW).
128
  These studies also fail to include current 
research on the increase of HPV-related anal cancer and head and neck cancer.
129
  However, 
                                                          
123 Daniel B. Fishbein et al., New, and Some Not-so-New, Vaccines for Adolescents and Diseases They 
Prevent, 121 PEDIATRICS S5, S10 (2008). 
124 Law, supra note 18, at 1748. 
125 Elissa Mendenhall, Guard Against Gardasil, 142 MOTHERING MAGAZINE May–June 2007, at 45, 49. 
126 See, e.g., Jane J. Kim & Sue J. Goldie, Health and Economic Implications of HPV Vaccination in the 
United States, 359 NEW ENG. J. MED. 821, 821 (2008) (asserting that it would be cost-effective to vaccinate only females 
for the benefit of the entire population, assuming there was a high proportion of vaccinated females); see also Harrell W. 
Chesson et al., Cost-Effectiveness of Human Papillomavirus Vaccine in the United States, 14 EMERGING INFECTIOUS 
DISEASE 244, 247 (2008) (demonstrating that the vaccine is highly cost-effective when focusing only on the benefit to 
females); Zimet, Potential Barriers, supra note 55, at 397 (describing the problems with most cost-benefit analysis models 
that focus solely on cervical cancer). 
127 Elamin H. Elbasha & Erik J. Dasbach, Impact of Vaccinating Boys and Men Against HPV in the United 
States, 28 VACCINE 6858, 6858 (2010).  To date, there are no cost-benefit studies of the HPV vaccine for all males, both 
who have sex with females and who have sex with males.  Significantly, a recent study of the incidence of HPV in males, 
which demonstrated high occurrence of HPV in males, concluded that more information about the prevalence and 
epidemiology of the infection is necessary for any “realistic cost-effectiveness” study to be conducted.  See generally 
GIULIANO ET AL., INCIDENCE AND CLEARANCE, supra note 19. 
128 See Harrell Chesson, HPV Vaccine Cost-Effectiveness: Updates and Reviews, CTRS. FOR DISEASE 
CONTROL & PREVENTION, ADVISORY COMM. ON IMMUNIZATION PRACTICES 23 (Feb. 24, 2011), www.cdc.gov/vaccines 
/recs/acip/ downloads/mtg-slides... /11-4-hpv-cost.pdf (asserting that the study relied on by the ACIP and CDC is limited 
because it only focuses on heterosexual HPV transmission between females and males).  See also Jane J. Kim & Sue J. 
Goldie, Cost Effectiveness Analysis of Including Boys in a Human Papillomavirus Vaccination Programme in the United 
States, BRIT. MED. J., Oct. 9, 2009, at 7. 
A limitation of our analysis is that we only represented heterosexual partnerships and therefore did 
not reflect HPV transmission among men who have sex with men, who face a high risk of anal 
cancer and may realise [sic] a greater benefit from HPV vaccination.  Such an analysis would 
require a more comprehensive model that includes a fuller range of sexual behaviours [sic] . . . . 
129 Mehanna, Oropharyngeal Carcinoma, supra note 47, at 880. 
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separate studies demonstrate that the vaccine is highly cost-effective for the MSM group, 
especially when focusing on both anal cancer and genital warts.
130
 
Current HPV vaccination policies, which target only females, are heteronormative, 
unfair, and ineffective.  Additionally, these policies fail to achieve herd immunity.  Universal 
vaccine administration, through state mandates, will successfully immunize the population and 
create desired levels of herd immunity because such policies will be inclusive and accessible to all 
segments of the population. 
III.  MANDATING THE HPV VACCINE IS SOUND HEALTH POLICY 
Though the medical community has reached a consensus on the necessity of widespread 
vaccinations, the HPV debate remains a deeply fraught social issue because it is implicated in 
controversial topics, such as vaccine safety, parental autonomy and adolescent sexuality.
131
  In 
order to mandate the HPV vaccination, states will have to include the vaccine in the list of 
required vaccinations for school attendance.  Studies have proven that school mandates are highly 
effective at immunizing the population because school-related laws are influential, respected, and 
followed.
132
  Proponents of mandating the HPV vaccination emphasize issues of herd immunity 
and achieving universal coverage across all sexual orientations and socioeconomic groups.
133
  
Opponents of an HPV vaccination mandate cite issues of unnecessary promotion and approval of 
adolescent sexual activity, abrogation of parental autonomy, and the lack of constitutional support 
because HPV is a sexually transmitted disease, making it different than other vaccines.
134
  To see 
how these arguments have played out in the past, the next section will examine the development 
of vaccination policies for another disease: Hepatitis B. 
A. The Hepatitis B Vaccine as Precedent 
The Hepatitis B vaccine has been cited as precedent for an HPV vaccination mandate.
135
  
                                                          
130 Kim, supra note 61, at 849. 
131 James Colgrove et al., HPV Mandates—Lawmaking Amid Political and Scientific Controversy, 363 NEW 
ENG. J. MED. 785, 785 (2010). 
132 Alan R. Hinman et al., Childhood Immunizations: Laws that Work, 20 J. L. MED. & ETHICS 122, 122 
(2002); see also Julie Y. Morita et al., Effect of a School-Entry Vaccination Requirement on Racial and Ethnic Disparities 
in Hepatitis B Immunization Coverage Levels Among Public School Students, 121 PEDIATRICS e547, e550–51 (2008) 
(asserting that school mandated vaccinations for Hepatitis B created more equitable coverage among middle school 
students of color). 
133 See Law, supra note 18, at 1764 (arguing that HPV vaccination should be mandated in schools in order 
to protect the long-term interests of women, low-income people, and racial minorities); see also Wood, supra note 9, at 34 
(stating that a universal HPV vaccine may be the only way to ensure that low-income Hispanic and African American 
women will have access to the vaccine). 
134 See Wood, supra note 9, at 34; Colgrove et al., supra note 131, at 787 (stating that some social 
conservatives object to mandatory HPV vaccination policies because they believe the policies undermine abstinence 
education efforts); Javitt et al., supra note 20, at 387–93 (illustrating the view that mandatory HPV vaccinations violate 
principles of parental autonomy); Law, supra note 18, at 1767–71 (stating that courts are unlikely to interfere with parental 
autonomy with regard to the HPV vaccine because the risk of contracting cancer is statistical and remote); see also Susan 
Levine, Parents Question HPV Vaccine, WASH. POST, Mar. 4, 2007, at C1 (exploring whether mandatory HPV 
vaccination policies encourage adolescents to be promiscuous or intrude upon principles of parental autonomy). 
135 See, e.g., Rothman & Rothman, supra note 122, at 782–83; Gillian Haber et al., The HPV Vaccine 
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Legal scholars cite it in support of the constitutionality of a HPV mandate,
136
 and medical 
professionals cite it in support of universal coverage.
137
  Hepatitis B is similar to HPV in that it is 
a highly contagious sexually transmitted disease.
138
  The experiences of the Hepatitis B vaccine 
shed light on three specific issues impacting the success of the HPV vaccine: (1) universality; (2) 
financing; and (3) sexuality. 
Similar to the HPV vaccine, the Hepatitis B vaccine was initially targeted at only a 
segment of the population when it was first approved in the 1980s.
139
  However, as discussed in 
Part II, policymakers soon realized that vaccinating only part of the population did not reduce the 
prevalence of the disease, and incidence of the disease actually increased between the 1980s and 
1990s.
140
  It was not until the vaccine was recommended for universal coverage in infants and 
adolescents by the ACIP in the 1990s that coverage rates began to increase, thus decreasing the 
prevalence of the disease.
141
  Of the Hepatitis B vaccination policies, vaccine expert James 
Colgrove asserted: 
[B]ecause the [Hepatitis B] virus spreads primarily among sexually active 
people and injection-drug users, some parents argued that the vaccine should be 
given only to those groups rather than to all children.  Such targeting of the 
vaccine, however, proved to be less effective than universal vaccination in 
reducing the incidence of the disease.
142
 
Funding was a concern for the Hepatitis B vaccine and affected its uptake in the general 
population.  Between the initial introduction of the Hepatitis B vaccine in the 1980s and an 
upsurge in coverage by the end of the 1990s, the federal government enacted the Vaccines for 
Children program, mentioned earlier.
143
  This program is credited with providing the funding 
necessary to support universal coverage of the Hepatitis B vaccination.
144
 
                                                          
Controversy, 20 J.  PEDIATRIC & ADOLESCENT GYNECOLOGY 325, 326 (2007) (“[W]e have the precedent of school-entry 
mandates for hepatitis B virus (HBV) vaccine, including „catch-up‟ requirements in most states for middle school entry.  
Like HPV, HBV is overwhelmingly a sexually transmitted infection (STI), with few documented cases of casual contact 
transmission.”). 
136 See, e.g., Kyra R. Wagoner, Comment, Mandating the Gardasil Vaccine: A Constitutional Analysis, 5 
IND. HEALTH L. REV. 403 (2008); Law, supra note 18, at 1757. 
137 See, e.g., Haber et al., supra note 135; see also Rothman & Rothman, supra note 122. 
138 See Hepatitis B Facts for Health Care Professionals, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#b1 (last visited Apr. 10, 2012); see also Monique H. Lawrence & Mark A 
Goldstein, Hepatitis B Immunization in Adolescents, 17 J.  ADOLESCENT HEALTH 234, 235 (1995) (establishing that one of 
the risks for children, in addition to risky sexual behavior, was that the disease could be passed through cuts and scrapes, 
as well as through shared razors and toothbrushes).  For an analysis of the Hepatitis B vaccine and use among adolescents 
see Susan L. Rosenthal et al., Hepatitis B Vaccine Acceptance Among Adolescents and Their Parents, 17 J.  ADOLESCENT 
HEALTH 248, 248 (1995). 
139 Rothman & Rothman, supra note 122, at 782. 
140 Id.; Lawrence & Goldstein, supra note 138, at 243–35. 
141 See Rothman & Rothman, supra note 122, at 782–83. 
142 James Colgrove, The Ethics and Polices of a Compulsory HPV Vaccination, 355 NEW ENG. J.  MED. 
2389, 2390 (2006). 
143 Rothman & Rothman, supra note 122, at 783; Rosenthal et al., supra note 138, at 254. 
144 Rothman & Rothman, supra note 122, at 783. 
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Unlike the HPV vaccine, controversy did not surround the Hepatitis B vaccine.
145
  
Although some parents and providers opposed the universal application of the Hepatitis B 
vaccination, the opposition was mostly in regards to cost and funding, and less about adolescent 
sexuality.
146
  There is significant public controversy over implementing the HPV vaccination, 
however, due largely to federal support of abstinence-only education and the rise of the Religious 




Current federal policies, in addition to the change in political climate, have affected the 
success of the HPV vaccine, differentiating its experience on the market from the Hepatitis B 
vaccine.  First, the Hepatitis B vaccination was recommended for universal use almost ten years 
after it was introduced on the market.  Contrarily, the HPV vaccine has only been on the market 
for five years to date.  Second, implementing the Hepatitis B vaccine included a struggle for 
federal funding, which led to the creation of Vaccines for Children.  This program already covers 
the HPV vaccination for both males and females, and so federal funding is not an issue for the 
HPV vaccine.  Cost, nonetheless, is an issue for the HPV vaccine; Gardasil is one of the most 
expensive vaccines recommended by the ACIP.
148
  However, programs like Vaccines for Children 
allow those who cannot afford the vaccine to get inoculated.  Additionally, Merck & Co. offers 
the vaccine for free to women over age eighteen who do not qualify for the Vaccines for Children 
program.
149
  Third, the political climate has become more protective of adolescent sexuality since 
the introduction of the Hepatitis B vaccine.  The experiences of the Hepatitis B vaccine 
demonstrate that targeting only a specific segment of the population for vaccination will be 
unsuccessful in reducing the disease‟s prevalence, even though the disease is sexually transmitted.  
Rather than repeating the mistakes of the Hepatitis B vaccine, policymakers should mandate 
universal coverage now to prevent further increased incidents of genital cancers.  The power to 
lower cancer rates in the United States is in the hands of policymakers.  How will they act? 
B.  It is Constitutional to Mandate 
In its seminal decision on mandatory vaccinations, the Supreme Court ruled in Jacobson 
                                                          
145 Monica J. Casper & Laura M. Carpenter, Sex, Drugs, and Politics: The HPV Vaccine for Cervical 
Cancer, 30 SOCIOLOGY OF HEALTH & ILLNESS 886, 896 (2008) (citing to a conversation the authors had with James 
Colgrove). 
146 Gary L. Freed et al., Universal Hepatitis B Immunization of Infants: Reactions from Pediatricians and 
Family Physicians Over Time, 93 PEDIATRICS 747, 750–51 (1994); Rosenthal et al., supra note 138, at 254 (“Previous 
studies examining physician attitudes towards hepatitis B immunization has shown that some practitioners have chosen not 
to implement AAP recommendations because of concerns about the hepatitis B vaccination policy, particularly the 
financial burden.”). 
147 For a succinct history of the rise of abstinence only education, see Danielle LeClair, Comment, Let’s Talk 
About Sex Honestly: Why Federal Abstinence-Only-Until-Marriage Education Programs Discriminate Against Girls, are 
Bad Policy, and Why They Should be Overturned, 21 WIS. WOMEN‟S L. J. 291, 293–99 (2006); see also Kelly Keefe & 
Amber Oleson, A New Twist on the Birds and the Bees: Adolescent Female Sexuality and the Debates Surrounding Access 
to Birth Control, Comprehensive Sex Education, and the HPV Vaccine, 28 CHILD. LEGAL RTS. J. 13, 20–22 (2008).  For a 
short discussion of the rise of the Religious Right in connection with the HPV vaccine, see Casper & Carpenter, supra 
note 145, at 892–93. 
148 Mendenhall, supra note 125, at 49. 
149 Merck Vaccine Patient Assistance Program, MERCK, http://www.merck.com/merckhelps/vaccines/home. 
html (last visited Apr. 10, 2012). 
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v. Commonwealth of Massachusetts in 1905 that it is within a state‟s police power to mandate 
vaccinations, as long as it is “for the common good, for the protection, safety, prosperity, and 
happiness of the people.”
150
  In Jacobson, a citizen refused to get the state-mandated smallpox 
vaccination.
151
  The Court held that it was within the power of the Massachusetts legislature to 
protect the commonwealth from a “disease which threatens the safety of its members.”
152
  This 
power is not unlimited, but must serve a “real or substantial relation” to public health and 
safety.
153
  States thus have a constitutional right to mandate a vaccination if a public health 
necessity exists and the vaccination has a reasonable relationship to that necessity.
154
 
States are allowed to mandate vaccinations for children as a condition of school 
attendance.
155
  In 1922, the Supreme Court in Zucht v. King upheld a local ordinance requiring 
vaccinations for school attendance as a valid exercise of state power due to the unique public 
health concern of a school setting, where children can easily communicate diseases.
156
  Currently, 
state-mandated vaccinations for school attendance are based on ACIP recommendations
157
 for 
certain highly contagious communicable diseases, including influenza, chicken pox, 
meningococcus, polio, and measles.
158
  State-mandated vaccinations have been highly effective in 
preventing outbreaks of the above-mentioned diseases, and studies show that outbreaks tend to 
occur in communities where vaccination exemptions are common.
159
  In general, school 
vaccination mandates are viewed positively as an efficient means to vaccinate the population, and 
are seen as beneficial to society as a whole. 
Opponents of a HPV vaccination mandate argue that such a mandate is unconstitutional 
because HPV is not an airborne disease transmitted in a school setting.
160
  These opponents argue 
that other diseases falling under state mandates for school attendance meet Jacobson‟s 
reasonableness requirement because “[a]ll children who attend school are equally at risk of both 
transmitting and contracting” these highly contagious diseases and as a result “a clear relationship 
exists between conditioning school attendance on vaccination and the avoidance of the spread of 
infectious disease within the school environment.”
161
  Additionally, it has been argued that HPV 
does not meet the Jacobson test because HPV and cervical cancer are not a “widespread 
epidemic” like smallpox at the time of Jacobson. 
Nonetheless, the HPV vaccine does meet the Jacobson test.  A state-mandated HPV 
                                                          
150 197 U.S. 11, 27 (internal citations omitted). 
151 Id. at 13. 
152 Id. at 27. 
153 Id. at 31. 
154 Tracey Solomon Dowling, Note, Mandating a Human Papillomavirus Vaccine: An Investigation into 
Whether Such Legislation is Constitutional and Prudent, 34 AM. J.L. & MED. 65, 66 (2008). 
155 James G. Hodge, Jr. & Lawrence O. Gostin, School Vaccination Requirements: Historical, Social and 
Legal Perspectives, 90 KY. L.J. 831, 857–58 (2001-2002) (“Despite the mandatory nature of compulsory school 
vaccination laws, the state‟s power to require children to be vaccinated as a condition of school entrance has been widely 
accepted and judicially sanctioned.”). 
156 260 U.S. 174, 177 (1922). 
157 Oleson, supra note 72, at 66. 
158 Javitt et al., supra note 20, at 389. 
159 Hinman et al., supra note 132, at 125. 
160 Javitt et al., supra note 20, at 389. 
161 Id. 
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vaccination is constitutional because it serves the rational purpose of working to achieve a health 
policy goal.
162
  HPV is a pressing health issue, and as such, vaccination is a public health 
necessity: “[P]eople infected with HPV are personally at risk of various diseases and . . . can 
easily transmit the virus and risk of disease to others.”
163
  Additionally, the vaccine has a 
reasonable relationship to public necessity because it has been proven highly efficacious, and 
thus, will benefit the population.  It is true that HPV is not an “infectious airborne disease,”
164
 but 
it is, nevertheless, highly contagious.
165
  Although HPV is not necessarily communicated in a 
school setting, the Hepatitis B vaccine experience suggests that school-attendance mandates can 
be applied to sexually transmitted diseases.  Mandating the vaccination is the most effective way 
to immunize the population and reduce the prevalence of HPV-related cancers and infections in 
the United States.  It is therefore constitutional and within a state‟s power to mandate the HPV 
vaccination for school attendance. 
C.  The Benefits Outweigh the Risks 
There were relatively few adverse events connected to the vaccine during clinical drug 
trials and very few side effects of the vaccine reported since it was first administered in 2006.
166
  
Most adverse events related to the vaccine in clinical trials involved pain at the injection site or 
fever.
167
  In studies conducted on females, there were very few serious adverse events.  In one 
study of 2,673 female participants, there was one serious adverse incident,
168
 and in a second 
study of 6,019 female participants there were seven serious adverse incidents.
169
  In this second 
study, conducted by Members of the Females United to Unilaterally Reduce Endo/Ectocervical 
Disease (FUTURE) II Study Group, the participants were followed for up to three years after 
administration of the vaccine, and within this extended period there was only a .01% risk of any 
serious adverse incident.
170
  There were fewer adverse incidents connected to the vaccine reported 
in studies of males in comparison to studies of females, which researchers attribute to the higher 
levels of muscle mass in males at injection sites.
171
  For the male-only studies, most adverse 
events reported in trials were not serious and, similar to the female-only trials, related to pain at 
the injection site or fever.
172
  In one study of male participants, there were no serious adverse 
                                                          
162 Law, supra note 18, at 1753–54 (arguing that HPV as a highly contagious disease and as such meets the 
principles set forth in Jacobson). 
163 Id. at 1753. 
164 Lawrence O. Gostin & Catherine D. DeAngelis, Mandatory HPV Vaccine: Public Health vs. Private 
Wealth, 297 JAMA 1921, 1922 (2007). 
165 Law, supra note 18, at 1754. 
166 Zimet, Potential Barriers, supra note 55, at 391. 
167 See Barbara A. Slade et al., Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus 
Recombinant Vaccine, 302 JAMA 750 (2009) (describing physical reactions to the vaccine injection); see generally 
Garland et al., supra note 63 (providing an analysis of an HPV vaccine trial); The FUTURE II Study Group, Quadrivalent 
Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions, 356 NEW ENG. J.  MED. 1915 (2007) 
[hereinafter The FUTURE II Study Group] (providing procedural information of an HPV vaccine trial). 
168 Garland et al., supra note 63, at 1934–35, 1940. 
169 The FUTURE II Study Group, supra note 167, at 1924. 
170 Id. 
171 Giuliano et al., HPV in Males, supra note 67, at 409. 
172 Id. 
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After a vaccine goes to market, all adverse incidents are reported to the Vaccine Adverse 
Event Reporting System (VAERS).  VAERS is co-sponsored by the FDA and the CDC and 
monitors vaccines after they have been administered to the population.
174
  VAERS monitors 
vaccines by receiving reports about adverse events from providers, manufacturers, and 
individuals.
175
  VAERS is described as “a national, voluntary, passive surveillance system.”
176
  A 
recent study on VAERS reports about the HPV vaccine demonstrated that significant adverse 
events are not associated with the vaccine.
177
  Researchers stated: “Our review of 12,424 reports 
of [reported adverse events] following receipt of [the] HPV [vaccine] after licensure found that 
most did not meet the FDA definition of serious.”
178
  The vaccine will continue to be monitored 
by VAERS, but current studies do show that the vaccine is safe. 
Researchers still do not know how long the effectiveness of the vaccine will last, and if 
those vaccinated will need a booster shot at some point.  Studies comparing the epidemiology of 
the vaccine to that of the Hepatitis B vaccine have been conducted in order to examine the 
potential long-term effectiveness of the vaccine.
179
  Studies of the Hepatitis B vaccine reveal that 
the long-term immunity of the vaccine is connected to its ability to induce immune memory in the 
body.
180
  Clinical trials of the HPV vaccine demonstrate that the drug is effective in inducing 
immune memory for at least up to five years,
181
 and that the development of the immune memory 
is similar to that of Hepatitis B. 
The fact that the long-term effectiveness of the vaccine is unknown is not a reason to 
discount the benefits and relatively low risks of the vaccine.  There are many vaccines currently 
administered that require subsequent booster shots.
182
  In a 2007 article on the risk and benefits of 
HPV, New York Times Medical Health Specialist Jane E. Brody asserted in response to an inquiry 
about the long-term safety and efficacy of the vaccine: “[W]e do have at least five years of safety 
data that include no hints of long-term risks or waning effectiveness.  But if the vaccine should 
begin to lose potency over time, that could easily be remedied by a booster shot.”
183
  Current data 
shows that the vaccine is highly effective and the risks of adverse events are very low.  Thus, the 
                                                          
173 Id. 
174 VACCINE ADVERSE EVENT REPORTING SYSTEM, http://vaers.hhs.gov/index (last visited Apr. 10, 2012). 
175 About the VAERS Program, VACCINE ADVERSE EVENT REPORTING SYSTEM, http://vaers.hhs.gov 
/about/index (last visited Apr. 10, 2012). 
176 See generally Slade et al., supra note 167 (describing minimal adverse physical reactions post-
vaccination). 
177 Id. at 755. 
178 Id. 
179 See, e.g., Kevin A. Ault, Long-Term Efficacy of the Human Papillomavirus Vaccination, 107 
GYNECOLOGIC ONCOLOGY S27, S29 (2007) (comparing Hepatitis B and HPV vaccine studies and finding that long-term 
vaccine efficiency is dependent on a “robust immune memory”). 
180 Id. 
181 Id. at S29–30. 
182 See Tetanus (Lockjaw) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/vaccines/vpd-vac/tetanus/default.htm (last visited Apr. 10, 2012) (discussing the need for a tetanus 
booster every ten years); Pertussis (Whooping Cough) Vaccination, CTRS. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/vaccines/vpd-vac/pertussis/default.htm (last visited Apr. 10, 2012) (discussing the booster shot for 
Pertussis, Tetanus, and Diptheria). 
183 Jane E. Brody, HPV Vaccine: Few Risks, Many Benefits, N.Y. TIMES, May 15, 2007, at F7. 
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benefits of the HPV vaccine clearly outweigh the risks, and the potential for vaccine risks, or even 
a reduction in immunity, should not weigh against mandating the vaccine for school attendance. 
D.  Good Health Policy 
Mandating the HPV vaccine is sound health policy.  A universal mandate will allow for 
timely coverage, broader education and higher levels of awareness, and prevent stigmatization of 
MSM and the exclusion of WSW.  Additionally, a universal vaccine will create higher levels of 
immunity throughout the population. 
Education is key to the success of the HPV vaccine.  Studies demonstrate that once 
awareness of HPV is increased, there is typically a desire to obtain the HPV vaccine.
184
  However, 
males are significantly less knowledgeable about HPV and the health consequences of HPV than 
females.
185
  Specifically, studies show that there is limited knowledge of HPV among MSM.
186
  In 
one study of gay and bisexual males, although very well aware that HPV was an STI, the 
participants often did not know that HPV could lead to genital warts, and even fewer knew that 
HPV could cause anal and penile cancer.
187
  Although the dearth of knowledge among males in 
general can be partly attributed to the focus of Merck & Co.‟s advertising campaign on females 
and parents of females,
188
 the lack of knowledge among males, regardless of sexuality, is 
alarming.  Scholars indicate that without mandating the vaccination, it will be hard to encourage 
males to get vaccinated at a young age because the parents of males have been unengaged in 
conversations around HPV and the vaccine.
189
 
Abstinence-only education across the United States prevents an increase in STI 
education.  Although conservatives argue that mandating the HPV vaccination will undermine 
efforts made by abstinence-only education and cause more adolescents to engage in sexual 
activities,
190
 this argument is built on a faulty foundation because countless studies have proven 
that abstinence-only education does not prevent adolescents from engaging in sexual activities.
191
  
In fact, abstinence-only education neither delays “the age of sexual initiation, nor . . . decrease[s] 
the number of sexual encounters” adolescents have.
192
  It is argued that abstinence-only education 
is actually dangerous for adolescents because it “leav[es] them perilously unaware, or even 
misinformed about genuine probable risks” of sex by not teaching about STIs or contraception.
193
  
                                                          
184 Monica Christine R. Nandwani, Men’s Knowledge of the Human Papillomavirus Vaccine, 35 NURSE 
PRACTITIONER 32, 38 (2010) (discussing a correlation between HPV awareness and an increased vaccination intent in 
men); see also Reiter et al., supra note 81, at 199 (observing that approximately 74% of male study participants were 
willing to get the HPV vaccine). 
185 Zimet & Rosenthal, supra note 109, at S26; Nandwani, supra note 184, at 36. 
186 Reiter et al., supra note 81, at 200. 
187 Id. at 199. 
188 Nandwani, supra note 184, at 37. 
189 Liddon et al., supra note 75, at 2. 
190 Wood, supra note 9, at 34; Colgrove et al., supra note 131, at 787. 
191 Bleakley et al., supra note 10, at 1152. 
192 R. Alta Charo, Politics, Parents, and Prophylaxis—Mandating HPV Vaccination in the United States, 
356 NEW ENG. J. MED. 1905, 1907 (2007); see also Michelle Fine & Sara I. McClelland, Sexuality Education and Desire: 
Still Missing After all These Years, 76 HARV. EDUC. REV. 297, 312 (2006) (discussing findings that abstinence-only 
programs do not delay intercourse). 
193 Globerson, supra note 18, at 89. 
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If knowledge is key to HPV administration and uptake in the population, then these programs 
create a concrete barrier to the reduction of HPV by failing to educate adolescents about STIs. 
STIs in general, and HPV in particular, are highly prevalent among adolescents and 
young adults.
194
  Studies demonstrate that HPV infection occurs at a higher rate right after an 
individual‟s sexual debut.
195
  Studies show that by age fourteen or fifteen, a significant percentage 
of adolescents have engaged in sexual activities and about twenty-five percent of adolescents 
have engaged in vaginal sex.
196
  It is argued that in states with high levels of abstinence-only 
education, adolescents are less likely to engage in vaginal or anal sex but are choosing oral sex at 
higher rates.
197
  Due to the rigidity of the abstinence-only education they are receiving, these teens 
are unaware of the STI risks associated with oral sex, and are unknowingly increasing their risk 
levels for HPV and other STIs that can be transmitted through oral sex.
198
  One study stated, 
“HPV DNA has been reported in approximately 20% of women who have never had vaginal 
intercourse, suggesting that abstaining from penetrative intercourse is not completely protective 
against infection.”
199
  Abstinence-only education fails to educate adolescents about STI risks from 
sexual activity, and thus adolescents remain highly susceptible to HPV transmission.  Researchers 
argue that only comprehensive sexual education, which speaks to the risks of STIs and teaches 
adolescents about contraception and safe sex, will reduce the high prevalence of sexually 
transmitted diseases among adolescents.
200
 
Opponents of the HPV vaccination argue that vaccinating adolescents for a sexually 
transmitted disease will give them a false sense of security and increase sexual activities.
201
  
However, this argument has never been proven to be correct.  A sociologist from the CDC was 
cited in the New England Journal of Medicine for the proposition that “fear of sexually 
transmitted diseases has not been a major motivation for adolescents to abstain from sex [] and the 
availability of condoms and emergency contraception has not had measurable effects on the 
frequency of unsafe behavior.”
202
  Comparisons to condom availability are made to refute the 
argument that the HPV vaccination will increase adolescent sexual activities.
203
  The availability 
of condoms in schools did not change the number of adolescents having sex, but rather, according 
to CDC studies, made adolescent sex safer by increasing condom usage.
204
  Additionally, studies 
                                                          
194 See, e.g., Susan L. Rosenthal & Lawrence R. Stanberry, Parental Acceptability of Vaccines for Sexually 
Transmitted Infections, 159 ARCHIVES OF PEDIATRIC & ADOLESCENT MED. 190, 190 (2005) (“About half of the 18 million 
new STI cases in 2000 were among those between 15 and 25 years of age.”). 
195 Forhan et al., supra note 103, at 1509–10. 
196 Gregory D. Zimet, Improving Adolescent Health: Focus on HPV Vaccine Acceptance, 37 J.  
ADOLESCENT HEALTH S17, S17 (2005); Bleakley et al., supra note 10, at 1151. 
197 Globerson, supra note 18, at 91. 
198 Id. 
199 Villa, supra note 97, at S1/23 (citing Catherine Ley et al., Determinants of Genital Human 
Papillomavirus Infection in Young Women, 83 J. NAT‟L CANCER INST. 997, 1003 (1991)). 
200 Forhan et al., supra note 103, at 1510. 
201 See generally Gibbs, supra note 9 (explaining that some opponents of the vaccination believe it will be 
detrimental to the sexual activities of teenagers); see also Globerson, supra note 18, at 89; Wood, supra note 9, at 34. 
202 Robert Steinbrook, The Potential of Human Papillomavirus Vaccines, 354 NEW ENG. J. MED. 1109, 1112 
(2006) (citing the opinion of Nicole Liddon, a CDC sociologist). 
203 Monk & Wiley, supra note 10, at 421. 
204 See id. (asserting that the HPV vaccine will not negatively affect teenage sexual relations since the 
availability of condoms has not). 
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have shown that access to emergency contraception has not increased adolescent sex or spurred 
younger adolescents to engage in sex.
205
  A 2006 article in the Journal of Obstetrics and 
Gynecology stated the point perfectly: “Seat belts do not cause reckless driving, tetanus shots do 




An additional argument against mandating the vaccination is that making it a 
requirement for school attendance undercuts parental autonomy because mandatory vaccinations 
necessarily impinge on a parent‟s decision to vaccinate his or her child.  The Supreme Court has 
stated repeatedly that parents have the fundamental right to control their child‟s upbringing.
207
  It 
has been argued that a parent‟s fundamental right to direct a child‟s upbringing extends to issues 
of birth control, sex, and the HPV vaccination.
208
  However, parental autonomy with respect to 
one‟s children is not limitless.
209
  Parental decisions based on religious beliefs or moral values are 
not allowed to subject children to harm.
210
  In 1944, the Supreme Court stated in Prince v. 
Massachusetts that “[p]arents may be free to become martyrs themselves.  But it does not follow 
that they are free, in identical circumstances, to make martyrs of their children . . . .”
211
  Parental 
autonomy can be limited by a mandated HPV vaccination, as it is with other school-mandated 
vaccinations.  HPV vaccine proponents should focus on the universal acquisition of the disease 
and its serious negative health consequences in order to encourage parental acceptance of the 
vaccine. 
Some argue that legislation with wide parental exemptions is the only appropriate way to 
enact HPV vaccination legislation.
212
  Although not constitutionally required to do so, states can 
allow exemptions to vaccination mandates,
213
 and states can choose not to allow exemptions.
214
  
All states must have medical exemptions,
215
 most have religious exemptions,
216
 and a small 
number allow for philosophical exemptions.
217
  However, in Prince v. Massachusetts, the 
Supreme Court asserted that religious rights can be preempted when societal values and welfare 
are threatened: “Thus, [a parent] cannot claim freedom from compulsory vaccination for the child 
more than for himself on religious grounds.  The right to practice religion freely does not include 
liberty to expose the community or the child to communicable disease or the latter to ill health or 
                                                          
205 See id. (citing a 2005 study on the effects of emergency contraception on sexual practices). 
206 Id. at 421. 
207 See supra note 5. 
208 Keefe & Oleson, supra note 147, at 14. 
209 Prince,  v. Massachusetts, 321 U.S. 158, 166 (1944). 
210 See id. (arguing that the state may infringe upon a guardian‟s decision pertaining to her child if it harms 
the child). 
211 Id. at 169. 
212 See Law, supra note 18, at 1768; see also Wood, supra note 9, at 34. 
213 Law, supra note 18, at 1768. 
214 See Workman v. Mingo Cnty. Sch., 667 F. Supp. 2d 679, 689 (S.D. W. Va. 2009) (citing case law from 
other states and district courts that do not allow exemptions for vaccines). 
215 Law, supra note 18, at 1765. 
216 See Anthony Ciolli, Religious & Philosophical Exemptions to Mandatory School Vaccinations: Who 
Should Bear the Costs to Society, 74 MO. L. REV. 287, 287 (2009) (asserting that West Virginia and Mississippi are the 
only two states that do not allow religious exemptions for mandatory vaccinations). 
217 Dowling, supra note 154, at 70. 
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There are two main arguments against allowing exemptions for an HPV vaccination 
mandate.  First, allowing exemptions prevents successful herd immunity.
219
  Unvaccinated 
children and adolescents are a potential threat to the general population, and specifically, if they 
are clustered together, are a threat to themselves because there is clear evidence that with less 
stringent vaccination requirements, there are more outbreaks of “vaccine preventable 
infections.”
220
  Second, parental decisions and adolescents‟ sexual choices are not necessarily in 
sync.  A parent‟s decision to not vaccinate his or her child might put that adolescent at risk, 
because regardless of what a parent believes, it is the adolescent‟s decision whether or not to have 
sex.
221
  According to a recent article in Pediatrics, “Because a substantial proportion of female 
adolescents acquire HPV infection soon after sexual initiation and parents typically fail to predict 
the timing of their daughters‟ sexual initiation, routine vaccination of preadolescent girls . . . is of 
critical importance.”
222
  Mandating the HPV vaccination will protect all males and females from 
dangerous health burdens, not for the sake of their parents, or based on their parents‟ religious 
beliefs,
223
 but for their own sake.  Thus, not only is it constitutional to mandate the HPV 
vaccination for school attendance, but it is also sound health policy to do so. 
IV. CONCLUSION 
As of July 2011, only Virginia and Washington D.C. had passed legislation mandating 
the vaccination for school attendance.
224
  Both laws have widely applicable opt-out provisions, 
which make it easy for parents to choose not to vaccinate their adolescents.
225
  In 2007, there were 
twenty states considering similar legislation, none of which were passed.
226
  The failure of these 
laws is attributed to the power of moral conservatives and the Religious Right.
227
  However, the 
tide is shifting.  There were significantly more bills proposed in state legislatures between 2009 
and 2010 than in previous years.  In the past two years, states have increasingly enacted 
                                                          
218 Prince, 321 U.S. at 166–68. 
219 Wagoner, supra note 136, at 435. 
220 Zimet, Potential Barriers, supra note 55, at 392; see also Wagoner, supra note 136, at 435–36. 
221 Renee Gerber, Mandatory Cervical Cancer Vaccinations, 35 J.L. MED. & ETHICS 495, 496 (2007). 
222 Forhan et al., supra note 103, at 1510. 
223 Gerber, supra note 221, at 495. 
224 D.C. CODE § 7-1651.04 (b)(1)(B)(iii) (2008); VA. CODE ANN. § 32.1-46 (D)(3) (2008); see also HPV 
Vaccine, NATIONAL CONFERENCE OF STATE LEGISLATURES, http://www.ncsl.org/default.aspx?tabid=14381 (last visited 
Apr. 10, 2012). 
225 VA. CODE ANN. § 32.1-46 (D)(3) (2008). 
Because the human papillomavirus is not communicable in a school setting, a parent or guardian, at 
the parent‟s or guardian‟s sole discretion, may elect for the parent‟s or guardian‟s child not to 
receive the human papillomavirus vaccine, after having reviewed materials describing the link 
between the human papillomavirus and cervical cancer approved for such use by the Board. 
Id.  D.C. CODE § 7-1651.04(b)(1)(B)(i) (2008) (“The parent or legal guardian [can object] in good faith [if] . . . the 
vaccination would violate his or her religious beliefs.”); D.C. CODE § 7-1651.04(b)(1)(B)(iii) (2008) (“The parent or legal 
guardian, in his or her discretion, [can elect] to opt out of the HPV vaccination program, for any reason.”). 
226 Casper & Carpenter, supra note 145, at 894. 
227 Id. at 892. 
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legislation mandating insurance coverage for the vaccine, funding the vaccine for uninsured or 
underinsured adolescents, or requiring education on the dangers of HPV.  This increase in 
legislative activity signals a recognition by policymakers of the importance of the HPV 
vaccine.
228
  However, there is more work to be done.  In addition to legislative efforts, more cost-
effectiveness analyses need to be completed to demonstrate that it is cost-effective to vaccinate 
the entire population.  More studies need to be completed on the long-term efficacy of the 
vaccine.  And education initiatives are necessary to educate the population on the dangers of HPV 
and the benefits of the vaccine. 
A 2010 study from Australia demonstrated high efficacy of the vaccine in reducing rates 
of genital warts.
229
  In April 2007, the Australian government started a program aimed at 
vaccinating all girls at age twelve.
230
  The program also included a catch-up vaccination for all 
females over the age of twelve.
231
  Researchers stated that prior to the introduction of the 
vaccination, rates of genital warts stayed relatively stable; however, after the government-initiated 
program, rates of genital warts among females dropped significantly.
232
  The study highlighted the 
high efficacy of the vaccine.  This Australian study is the first non-clinical study of a 




In the United States, there are larger societal issues implicated by the HPV vaccine 
controversy.  Abstinence-only education is not working and is putting adolescents at risk.  
Comprehensive sexual education is necessary; federal dollars should be spent on educating teens 
about safe sex and contraception.  Discourses on the sexual health of men who have sex with 
men, and women who have sex with women need to be included in sexual education classes as 
well.  The heterosexual focus of medical conversations needs to be redirected, and health policies, 
particularly sexual health polices, need to focus on all members of the population.  The HPV 
vaccine will benefit the public, and will reduce the prevalence of certain cancers in the United 
States.  Mandating the vaccine will efficiently and effectively immunize the population and be 
beneficial to public health.  In the case of HPV, inclusion is key, so that all members of society 
are included, and no group is left out. 
 
                                                          
228 See HPV Vaccine, NATIONAL CONFERENCE OF STATE LEGISLATURES, supra note 224 (explaining that 
twenty states have enacted legislation regarding the HPV vaccine). 
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